1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Selected patient characteristics from the overall patient population and in patients with and without FHPa
VariablePopulation (n = 2216)FHP (n = 1624)No FHP (n = 592)Odds Ratio95% CI
Demographics
    Age (yr)71.4 (20)72 (19.5)69.7 (21)1.01b1.00–1.01
    Female sex958 (43.3)723 (44.6)235 (39.8)1.22b1.01–1.48
    Preexisting mRS score0 (1)0 (1)0 (1)0.960.87–1.05
    Anticoagulation at onset211 (9.6)158 (9.8)53 (9)1.100.80–1.54
Clinical presentation
    Admission NIHSS (points)8 (11)10 (12)4 (4)1.21b1.18–1.24
    Aphasia831 (38)743 (46.4)88 (15)4.91b3.85–6.32
    Hemineglect583 (26)555 (35)28 (4.8)10.70b7.36–16.2
    Decreased level of consciousness252 (11.6)226 (14.3)26 (4.5)3.58b2.40–5.55
    Sensory deficit1237 (56.9)1021 (64.1)216 (37.1)3.03b2.49–3.69
    Visual field defect882 (40.6)836 (52.6)46 (7.9)13.00b9.58–18.07
Stroke localization
    Pure posterior circulation394 (18)182 (11.3)212 (36.9)0.22b0.17–0.27
    Pure anterior circulation1657 (75.4)1393 (86.6)254 (44.3)8.12b6.54–10.12
Stroke mechanism
    Atherosclerotic301 (14.1)249 (15.8)52 (9.2)1.87b1.37–2.58
    Cardioembolic729 (34)633 (40.2)96 (16.9)3.31b2.61–4.23
    Lacunar238 (11.1)42 (2.7)196 (34.5)0.05b0.04–0.07
Risk factors
    Atrial fibrillation619 (28)536 (33.1)83 (14)3.03b2.36–3.92
    Hypercholesterolemia1606 (73.1)1147 (71.2)459 (78)0.70b0.56–0.87
Acute CT imaging
    Onset-to-CT time (hr)4.3 (10.4)3.5 (8.6)8.1 (12.9)0.96b0.95–0.97
    Early ischemic changes on NCCT831 (38.2)771 (48.5)60 (10.3)8.20b6.21–10.99
    Arterial pathology in ischemic territory242 (16.2)237 (20.7)5 (1.4)18.01b8.19–50.89
  • ↵a Data are summarized as medians (with interquartile range) for continuous variables and as absolute numbers (with percentage) for categoric ones.
  • ↵b Statistically significant.